Global in situ hybridization market is valued USD 0.79 billion in 2020 and expected to reach USD 1.32 billion by 2027, registering a substantial CAGR of 7.6% in the forecast period of 2020-2027. This rise in the market can be attributed to the automation in diagnostic kits and real time for accurate diagnosis of cytogenetic modifications, rise in research and development related to the application of ISH in testing of infectious diseases and increase in number of incidences of cancer.
In situ hybridization is a technique which helps in precisely localization of particular segment of nucleic acid in a histologic section. The DNA or RNA probe is used in detecting complementary genetic material in tissues or cells. In situ hybridization is specifically useful in neuroscience. In situ hybridization has wide applications in microbiology, pathology, developmental biology, karyotyping & phylogenetic analysis and physical mapping.
The COVID-19 outbreak is an unprecedented global public health challenge and is expected to have a significant impact on the ISH market for diagnostics and research applications.
Although RT-PCR is widely used to detect and diagnose coronavirus in human samples, researchers and diagnostics companies across the globe are finding cost-effective and sensitive assay kits to deal with the pandemic. Molecular cytogenetics tests such as ISH play a role in identifying infected cells or tissue. As a result, in 2020, some companies in this market have focused on launching COVID-19 specific probes. A US-based firm, Creative Bioarray (US), launched a 2019 Novel Coronavirus Detection FISH Probe for the detection of viral particles in cells. Bio-Techne (US), is helping researchers with its RNAscope technology that allows the visualization of viral loads in cell and tissues using its V-nCoV2019-S probe.
With its applications in infectious disease diagnostics, the impact of COVID will have a short-term positive effect on the ISH market.
This market segments the global in situ hybridization market based on product, technology, application, end user, and region. Based on Product market is categorized into Consumables, Instruments, Software. Based on Technology, it is categorized into fluorescence in situ hybridization (FISH) and chromogenic in situ hybridization (CISH). Based on Application it is classified into Cancer Diagnosis, Immunology, Neuroscience, Cytology, and Infectious Diseases. Based on End User, it is bifurcated Hospitals & Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, Contract Research Organizations (CROS), and Academic & Research Institutions. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
North America accounted for the largest revenue share in 2018. High incidence rate of genetic disorders leading to birth defects, developmental disabilities, and other metabolic syndromes are some of the factors attributed to the growth. According to the Centers for Disease Control and Prevention (CDC), in 2017, around 3% to 4% of newborns in the U.S. were born with genetic abnormalities. Approximately 10% of adults and 30% of children in the country were hospitalized owing to genetic disorders. Fluorescent ISH is estimated to provide 98% accuracy in the detection of chromosomal aberrations leading to such disorders.
In addition, usage of these assays in various diseases such as cancer and genetic disorders is on the rise in this region and is further expected to drive the demand. Rising awareness among people regarding early diagnosis of genetic disorders, increasing disposable income, and highly established R&D infrastructure are the key factors attributed to the market growth. Favorable healthcare reimbursement policies and government reforms are anticipated to push the industry further.
Asia Pacific is anticipated to showcase lucrative growth in the forthcoming years. The industry is growing in terms of revenue generation from the cytogenetics and molecular diagnostic sectors in this region. The presence of supportive government initiatives pertaining to the increasing investments by manufacturers and government in the biotechnology sector and high untapped opportunities are the important factors propelling the regional growth.
In addition, continuous R&D activities for cancer treatment facilitate the demand for cancer research and are expected to fuel the regional demand in the near future. Growing adoption of new techniques for molecular-based cytogenetics, increasing outsourcing activities, and demand for early diagnosis and detection of diseases are anticipated to propel the regional growth.
Some of the key market players operating are Abbott Laboratories, F. Hoffmann-La Roche Ltd, Agilent Technologies, Abnova Corporation, BioGenex Laboratories, Bio-Techne Corporation, Biocare Medical, and Bio SB and Others.
In situ hybridization is a technique which helps in precisely localization of particular segment of nucleic acid in a histologic section. The DNA or RNA probe is used in detecting complementary genetic material in tissues or cells. In situ hybridization is specifically useful in neuroscience. In situ hybridization has wide applications in microbiology, pathology, developmental biology, karyotyping & phylogenetic analysis and physical mapping.
The COVID-19 outbreak is an unprecedented global public health challenge and is expected to have a significant impact on the ISH market for diagnostics and research applications.
Although RT-PCR is widely used to detect and diagnose coronavirus in human samples, researchers and diagnostics companies across the globe are finding cost-effective and sensitive assay kits to deal with the pandemic. Molecular cytogenetics tests such as ISH play a role in identifying infected cells or tissue. As a result, in 2020, some companies in this market have focused on launching COVID-19 specific probes. A US-based firm, Creative Bioarray (US), launched a 2019 Novel Coronavirus Detection FISH Probe for the detection of viral particles in cells. Bio-Techne (US), is helping researchers with its RNAscope technology that allows the visualization of viral loads in cell and tissues using its V-nCoV2019-S probe.
With its applications in infectious disease diagnostics, the impact of COVID will have a short-term positive effect on the ISH market.
This market segments the global in situ hybridization market based on product, technology, application, end user, and region. Based on Product market is categorized into Consumables, Instruments, Software. Based on Technology, it is categorized into fluorescence in situ hybridization (FISH) and chromogenic in situ hybridization (CISH). Based on Application it is classified into Cancer Diagnosis, Immunology, Neuroscience, Cytology, and Infectious Diseases. Based on End User, it is bifurcated Hospitals & Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, Contract Research Organizations (CROS), and Academic & Research Institutions. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
North America accounted for the largest revenue share in 2018. High incidence rate of genetic disorders leading to birth defects, developmental disabilities, and other metabolic syndromes are some of the factors attributed to the growth. According to the Centers for Disease Control and Prevention (CDC), in 2017, around 3% to 4% of newborns in the U.S. were born with genetic abnormalities. Approximately 10% of adults and 30% of children in the country were hospitalized owing to genetic disorders. Fluorescent ISH is estimated to provide 98% accuracy in the detection of chromosomal aberrations leading to such disorders.
In addition, usage of these assays in various diseases such as cancer and genetic disorders is on the rise in this region and is further expected to drive the demand. Rising awareness among people regarding early diagnosis of genetic disorders, increasing disposable income, and highly established R&D infrastructure are the key factors attributed to the market growth. Favorable healthcare reimbursement policies and government reforms are anticipated to push the industry further.
Asia Pacific is anticipated to showcase lucrative growth in the forthcoming years. The industry is growing in terms of revenue generation from the cytogenetics and molecular diagnostic sectors in this region. The presence of supportive government initiatives pertaining to the increasing investments by manufacturers and government in the biotechnology sector and high untapped opportunities are the important factors propelling the regional growth.
In addition, continuous R&D activities for cancer treatment facilitate the demand for cancer research and are expected to fuel the regional demand in the near future. Growing adoption of new techniques for molecular-based cytogenetics, increasing outsourcing activities, and demand for early diagnosis and detection of diseases are anticipated to propel the regional growth.
Some of the key market players operating are Abbott Laboratories, F. Hoffmann-La Roche Ltd, Agilent Technologies, Abnova Corporation, BioGenex Laboratories, Bio-Techne Corporation, Biocare Medical, and Bio SB and Others.
- Aerospace and Defense
- Agriculture
- Automotive and Transportation
- Business and Finance
- Chemical and Materials
- Consumer Goods and Retails
- Electronics and Semiconductor
- Energy and Power
- Food and Beverages
- Machinery and Equipment
- Manufacturing and Construction
- Medical Devices
- Pharmaceuticals and Healthcare
- Service and Software
- Technology, Media and Telecommunications
- Travel and Tourism
